NCT00531583

Brief Summary

Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation program for pts w/AML in 1st \& 2nd complete remission w/no HLA matched related donor

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2001

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2001

Completed
6.6 years until next milestone

First Submitted

Initial submission to the registry

September 17, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 19, 2007

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

January 5, 2016

Status Verified

January 1, 2016

Enrollment Period

14.3 years

First QC Date

September 17, 2007

Last Update Submit

January 4, 2016

Conditions

Leukemia, Monocytic, Acute

Keywords

AML in 1st & 2nd complete remission w/no HLA matched related donor

Outcome Measures

Primary Outcomes (1)

  • Efficacy

    2009-2015

Interventions

Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantationDRUG

Autologous PBSCT

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with AML in 1st \& 2nd complete remission w/no HLA matched related donor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

KFSH&RC

Riyadh, 1211, Saudi Arabia

Location

MeSH Terms

Conditions

Leukemia, Monocytic, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid, AcuteLeukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Fahad AlMohareb

    KFSH&RC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2007

First Posted

September 19, 2007

Study Start

March 1, 2001

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

January 5, 2016

Record last verified: 2016-01

Locations

SA(1)